Coronary Artery Disease

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

A score derived from machine learning that included information from stress cardiac magnetic resonance effectively predicted 10-year all-cause death in patients with known or suspected CAD, researchers reported at EuroEcho 2021.

In patients with three-vessel CAD and/or left main disease, those with heavily calcified lesions had elevated long-term mortality risk, which did not vary by assignment to PCI or CABG, according to new data from the SYNTAXES study.

FFR-guided PCI or CABG in patients with three-vessel CAD.

Svelte Medical Systems announced the FDA approved two of its drug-eluting stent systems designed to facilitate transradial PCI.

Among patients undergoing maintenance hemodialysis, high-dose IV iron reduced the rate of fatal or nonfatal MIs over 2 years compared with lower-dose iron, according to an analysis of the PIVOTAL trial published in Cardiovascular Research.

Ticagrelor added to low-dose aspirin reduced the risk for spontaneous MI, MI related to stent thrombosis and STEMI compared with placebo in patients with diabetes and CAD, according to a new analysis of the THEMIS trial.

Healio and Cardiology Today have curated a list of the most-read headlines from TCT 2021.

Among patients with left main CAD, the incidence of MACCE was similar with coronary revascularization in male and female patients, according to 10-year results of the PRECOMBAT trial.

In a new analysis from AFIRE, among patients with atrial fibrillation and stable CAD with prior coronary stenting, rivaroxaban monotherapy was superior to rivaroxaban plus an antiplatelet agent in both efficacy and safety.